Takeda Pharmaceutical Co Ltd (NYSE:TAK)
| 14.06 Delayed Data As of Dec 08 |  -0.02 / -0.14%Today’s Change | 13.19 Today|||52-Week Range 17.15 | -9.87% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $44.4B |
Company Description
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Contact Information
Takeda Pharmaceutical Co., Ltd. 4-1-1 Dosho-machi Osaka Osaka 540-8645 |
Employees
Shareholders
| Other institutional | 1.97% |
| Mutual fund holders | 0.56% |
| Individual stakeholders | -- |
Top Executives
| Christophe Weber | President, CEO & Director |
| Constantine Saroukos | Chief Financial Officer & Director |
| Andrew S. Plump | Director, President-Research & Development |
| Michael E. Mendelsohn | Chief Medical & Scientific Officer |
| Gabriele Ricci | Chief Data & Technology Officer |
